Immunology

Urology Care Foundation Announces 2024 Research Awards of Distinction

Retrieved on: 
목요일, 4월 4, 2024
Western University, Research, American Urological Association, Xenobiotic, Translational research, Postdoctoral researcher, Prostate cancer, Environment, Lawson Health Research Institute, Immunology, Committee, Gut microbiota, University, Macrophage, Doctor of Philosophy, Role, Publication, Pediatrics, University of California, Pediatric urology, Division, FACS, Radiation therapy, Society, Michigan Medicine, Nursing

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- The Urology Care Foundation, the world’s leading nonprofit urological health foundation and the official foundation of the American Urological Association, is pleased to announce the recipients of the 2024 Research Awards of Distinction.
  • "We are optimistic about the future of urologic research with the selection of the recipients of this year’s Urology Care Foundation Research Awards,” said Harris M. Nagler, MD, Urology Care Foundation President.
  • “We are thrilled with the Urology Care Foundation Research Awards of Distinction awardees this year,” said Steven Kaplan, MD, Chair of the AUA’s Research Council.
  • The awardees will be celebrated at the Urology Care Foundation Research Honors Program held at the AUA Annual Meeting in May 2024.

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Retrieved on: 
화요일, 4월 2, 2024
Independent, Business school, Bachelor of Science, Engineering, Bristol Myers Squibb, Thayer School of Engineering, Immunology, Therapy, Corporate development, Corporation, True north, ICON PLC, Business, Dartmouth College, Biogen, ATP, Genzyme, Cardiology, Biomedical engineering, Novo Nordisk, Drug discovery, Tuck School of Business, Acquisition, University, MBBS, AbbVie, Bioverativ, ICON, CBO, Columbia University, Biology, MBA, Hidradenitis suppurativa, TRML, Partner, Military, Management

The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Key Points: 
  • The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
  • The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.
  • He has spent over a decade specializing in founding, building and investing in biotech companies.
  • Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Retrieved on: 
목요일, 3월 28, 2024
Synthetic media, Neuroscience, Growth, Urology, Partnership, Knowledge, Acquisition, Health Canada, Immunology, Investment, Safety, PMDA, Trilogy, Endocrinology, Generative

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Key Points: 
  • PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
  • The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
  • Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
  • It applies its expertise and unique approaches to deliver quality medical writing output.

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Retrieved on: 
수요일, 3월 27, 2024
Seyfarth Shaw, Synthetic media, Neuroscience, Growth, Urology, Partnership, Knowledge, Acquisition, Health Canada, Immunology, Investment, Safety, PMDA, Trilogy, Endocrinology, Generative

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Key Points: 
  • PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
  • The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
  • Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
  • It applies its expertise and unique approaches to deliver quality medical writing output.

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Retrieved on: 
월요일, 4월 8, 2024
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Wolfram syndrome, Medication, Metabolism, Patient, AMX0035, Samuel, Immunology, Doctor of Philosophy, MD, Trial of the century, Amylyx Pharmaceuticals, Division, Disorder, Pathology, Pharmaceutical industry

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.

Key Points: 
  • A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.
  • Dr. Fumihiko Urano is a physician and medical researcher specializing in Wolfram syndrome.
  • Dr. Urano is a driving force in the study of Wolfram syndrome and related disorders, including WFS1-related disorders/Wolfram-like disorders.
  • As director of the Wolfram Syndrome Clinic and the Wolfram Syndrome International Registry & Clinical Study at Washington University, Dr. Urano treats patients with Wolfram syndrome and related disorders, and leads basic science, clinical, translational, and interventional studies of Wolfram syndrome and related disorders.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
화요일, 4월 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
수요일, 3월 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Retrieved on: 
목요일, 4월 4, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Inflammation, Harvard Medical School, DSP, Development, Gene expression, Immunotherapy, IL-6, Triple-negative breast cancer, RNA, King's College London, Immunology, Tumor microenvironment, Cancer, University, NanoString Technologies, Senior, Biology, Abstract, Pancreatic cancer, Neoplasm, Research and development, Hospital, Cell, SMI, MD Anderson Cancer Center, Blind spot, Medical imaging

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.

Key Points: 
  • NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.
  • The conference will be held in San Diego, April 5-10, 2024.
  • NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms.
  • “NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today.

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
수요일, 4월 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
수요일, 4월 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.